Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158951 · ClinicalTrials.gov registry record · Phase 2
Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF
A Phase 2 study of Congestive Heart Failure, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 1
- Study location
NCT00158951: Completed Phase 2 study of Congestive Heart Failure, sponsored by Boston Scientific Corporation.
NCT00158951 is a Phase 2 study of Congestive Heart Failure that has completed, run by Boston Scientific Corporation. The registered enrollment target is 360 participants, above the 323-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158951, a Phase 2 study of Congestive Heart Failure, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the CONTAK® RENEWAL™ 2/4/4HE cardiac resynchronization therapy defibrillator (CRT-D) family and EASYTRAK® 2 lead in delivering LV-CRT or BiV-CRT with an LV Offset for patients with heart failure and an indication for an ICD.
Conditions Studied
Interventions
- DEVICE CONTAK RENEWAL 2/4/4HE CRT-D
- DEVICE EASYTRAK 2 Lead
Study Locations (1)
Minnesota
- Multiple Locations in the US - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-10 |
| Phase | Phase 2 |
What the finished NCT00158951 record still lists
NCT00158951 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 323-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which CONTAK RENEWAL 2/4/4HE CRT-D is the first listed.
NCT00158951 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00158951 about?
NCT00158951 is a clinical study titled "Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF". The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the CONTAK® RENEWAL™ 2/4/4HE cardiac resynchronization therapy defibrillator (CRT-D) family and EASYTRAK® 2 lead in delivering LV-CRT or BiV-CRT with an LV Offset for patients with heart failure and an indic...
What is the current status of trial NCT00158951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2003-03. Estimated completion is 2004-10.
What conditions does trial NCT00158951 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT00158951?
The interventions under investigation include: CONTAK RENEWAL 2/4/4HE CRT-D (DEVICE), EASYTRAK 2 Lead (DEVICE).
Who is sponsoring clinical trial NCT00158951?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00158951 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00158951's enrollment target sits among peer trials
360 12th of 51 higher than 40 of 51 other Congestive Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 2
-
At-Home Automated External Defibrillator (AED) Training Study
COMPLETED · Phase 2
-
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes
COMPLETED · Phase 2
-
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
COMPLETED · Phase 2
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia